- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00874159
A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines (DiabCare Asia)
October 31, 2023 updated by: Novo Nordisk A/S
DiabCare Asia 2008 Philippines A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Philippines & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Philippines
This study is conducted in Asia.
The aim of this observational study is to describe the diabetes management, control status and complication profile in a diabetic population of Philippines.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
770
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Manilla, Philippines, 1605
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to inclusion and exclusion criteria.
Description
Inclusion Criteria:
- Diabetic patients registered in the particular centre for more than 12 months
- Patients should have visited the centre at least once in the last 3-6 months apart from the initial visit
- Patients willing to sign informed consent form
Exclusion Criteria:
- Repetition of any patient as patients should not be included twice for any reason
- Unwilling to participate or unable to comply with protocol requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
A
|
Subject will only fill out a questionaire when entering the observational study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean duration of diabetes in type 1 and type 2 patients respectively
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean duration of treatment of type 2 DM
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean HbA1c of diabetic patients
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients having dyslipidemia and hypertension
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients having cardiovascular complications
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients having peripheral vascular disease
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients having diabetic eye complications
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients having diabetic nephropathy
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean age of onset of type 1 diabetes mellitus
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean age of onset of type 2 diabetes mellitus
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of patients on Insulin therapy
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of patients on OAD therapy
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean FPG of diabetic patients
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Mean PPG of diabetic patients
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients with HbA1c target below 7.0%
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Percentage of diabetic patients with HbA1c target below 6.5%
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of diabetes associated with highest number of diabetic complications
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Patients' perception will be analysed through Patient questionnaire measuring: Psychological well-being, Quality of life, Patients' compliant to treatment
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Physician perception of diabetes and its management will be analysed through Physician questionnaire measuring awareness about:o HbA1c test and its goal,Anti-diabetic treatment,Barriers towards optimum diabetes control
Time Frame: at baseline visit/study start
|
at baseline visit/study start
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Global Clinical Registry (GCR, 1452), Novo Nordisk A/S
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
March 31, 2009
First Submitted That Met QC Criteria
April 1, 2009
First Posted (Estimated)
April 2, 2009
Study Record Updates
Last Update Posted (Actual)
November 2, 2023
Last Update Submitted That Met QC Criteria
October 31, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INS-3712
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on No treatment given
-
Robert G. Grossman, MDThe University of Texas Health Science Center, Houston; University of Maryland... and other collaboratorsRecruitingSpinal Cord InjuryUnited States, Canada
-
Novo Nordisk A/SEnrolling by invitationSystemic Inflammation | Chronic Kidney Disease (CKD) | Atherosclerotic Cardiovascular Disease (ASCVD)United States
-
Novo Nordisk A/SEnrolling by invitationHeart Failure | Chronic Kidney Disease | Cardiovascular RiskKorea, Republic of, China, United States, Argentina, Germany, Canada, Poland, Brazil
-
Novo Nordisk A/SEnrolling by invitationParkinson DiseaseUnited States, Japan, Sweden, United Kingdom
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedNon-alcoholic Steatohepatitis (MASH) | Non-alcoholic Fatty Liver Disease (MASLD)India
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedType 2 DiabetesKorea, Republic of, Mexico, India, United Kingdom, Australia, France, Saudi Arabia
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare ProfessionalsSpain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States